Apatinib plus ifosfamide and etoposide versus ifosfamide and etoposide in patients with advanced osteosarcomas (OAIE/PKUPH-sarcoma 11): a randomized phase II study.

Nat Commun · 2025 · PMC12647724 · PMID 41290609

Europe PMC DOI

hedged sentence

0.0598

closest p · 1.2× alpha

0.0598

boldest claim

The sentences

did not reach statistical significanceP = 0.0598so close (0.05 < p ≤ 0.1)

Crucially, PFS was analyzed with censoring at the time of local therapy, whereas EFS counted initiation of subsequent anti-tumor therapy, including local therapy, as an event; under this definition, the between-group difference in EFS did not reach statistical significance (HR 0.64; 95% CI 0.40–1.02; nominal P = 0.0598).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.